Per Wester - The neurologist's perspective: insights in AF-thromboembolic events prevention

Posted on 19-02-16

About this lecture

The Neurologist point of view: review of the published evidence and the consensus on bleeding+stroke risk assessments in AF patients. when approaching antithrombotic therapy in AF patients. Includes uptake of the LAAO recommendation in the ESC guidelines and what that means to Neurologists. Many Cardiologists do not really know what Neurologist think and the reasoning. What it does it mean to the every day practice, and the annual number of ICH on NOAC or VKA for the average neurology practice?

Subjects related to this video

Clinical Evidence Indications & Referral Patient Information Scientific Meetings

Related video's

David Hildick Smith - What’s new: clinical data published and presented since last year

New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Clinical Evidence Scientific Meetings

Matthew Price - What’s new: cost effectiveness and health economics

Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
Clinical Evidence Scientific Meetings

John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?

John Camm, UK vs Hans Christoph Diener, DEU    Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!
Clinical Evidence Indications & Referral Patient Information
+1
To lecture overview